Pack · 11 talks · 3h 33m to watch, 63 min to read

AI in high-risk domains

High-risk AI is not one field, and its controls cannot be copied whole from one industry to another. A government lab worries about classified data and kinetic consequences; tax, finance, legal and clinical systems fail in different ways. Each needs autonomy matched to the task, deterministic checks around irreversible decisions, and clear rules about where data may run. Cryptographic controls and provenance can protect evidence, but they do not decide whether an agent should act. That requires explicit workflow state, receipts people can inspect, and evals built from expert judgment. Clinical systems add one final constraint: staged evidence must come before real patients enter the loop. Autonomy can grow, but only when the evidence supporting it grows too.

1
Mark Myshatyn, Los Alamos National Laboratory · 16:31 · AI Engineer World's Fair 2025
Government Agents: AI Agents Meet Tough Regulations

Why first: Myshatyn starts with the consequences that every later control has to answer: exposed national-security data, harmful outcomes and public scrutiny. Hron follows by turning that broad government risk into a practical question for each professional workflow: how much agency should this task get?

4
Bilge Yücel, deepset GmbH · 19:09 · AI Engineer Europe 2026
What Breaks When You Build AI Under Sovereignty Constraints

Why here: Agrawal makes the decision path deterministic; Yücel widens the boundary to processing location, permissions, models and infrastructure. Traceability must survive those changes. Korshakov follows with a cryptographic answer to the hardest version of that problem: even the operator should not be trusted by default.

7
Anant Shankhdhar, Risa Labs · 16:41 · AI Engineer World's Fair 2026
Can Oncology Workflows Run Without Human Touch?

Why here: Ganesh requires a provenance chain for every result; Shankhdhar reconciles payer rules, documents, history and portal checks before granting an oncology workflow more autonomy. When clinical evidence is thin, a person takes over. Smoker shows why that caution matters even when each individual agent looks accurate.

8
Tom Smoker, WhyHow · 19:13 · AI Engineer World's Fair 2025
Knowledge Graphs in Litigation Agents

Why here: Shankhdhar gates each case on the evidence available; Smoker explains why a longer chain needs explicit state as well. Small errors compound across sequential agents, so his legal workflow stores inspectable relationships in a graph. Conover follows by asking how a human can inspect that evidence without drowning in it.

10
Akele Reed, Dave Revere & Doug Keller, SonderMind · 21:17 · AI Engineer World's Fair 2026
Evals-Driven Development for a Mental Health AI Coach

Why here: Conover gives experts receipts to inspect; Reed, Revere and Keller capture what clinicians find there as typed evals in CI. Their guardrails aim for the right intervention, not the most intervention. Joselowitz then asks how much evidence those evals need before a patient ever hears the system.

11
Jared Joselowitz, Ufonia · 19:15 · AI Engineer World's Fair 2026
Shipping AI to a Million Patients Without an A/B Test

Why last: Reed, Revere and Keller turn clinical judgment into release gates; Joselowitz builds the deployment ladder around them. He starts with specific harms, tests them in simulation, then moves through supervised evaluation toward monitored patient use. It closes the pack with its governing rule: autonomy is earned by staged evidence, not assumed at launch.